The MammoScreen project: Inclusiveness, accessibility, sustainability.

The MammoScreen project: Inclusiveness, accessibility, sustainability.

MammoScreen Project

MammoScreen is a project co-funded by the European Union and the UK Research and Innovation agency. It is set up with the aim of generating clinical evidence on the use of MammoWave®, a medical device based on microwave frequencies, for breast cancer prevention. The project involves seven international partners from Italy, Portugal, Spain and the UK.
MammoScreen aims to support the validation of an innovative, safe and non-invasive solution for the detection of breast cancers.

Discover the MammoScreen Project

GOVERNANCE

The MammoScreen partners

See all governance

OVERVIEW

An opportunity to advance in breast cancer detection

Breast cancer is the most common cancer in women worldwide, affecting 1 in 8 women. The World Health Organisation estimates that in 2022, worldwide cases of breast cancer accounted for 23.8% of all cancers in women, with 2.26 million women diagnosed with cancer and 66,10% deaths globally. While mammography is the gold standard technology for breast cancer screening – it has been demonstrated through different randomized controlled trials to reduce breast cancer mortality1,2,3 – it still has few limitations and drawbacks, such as the use of ionising radiations, breast compression, and with an overall reduced performance in the case of women with dense breast4 and in some types of hidden cancers.

Join our Community

Find out the latest news about MammoScreen world and stay up to  date with the project.

TECHNOLOGY

MammoWave®: a medical device for breast lesion detection

MammoWave® is a new microwave-based technology, patented and developed by the project partner Umbria Bioengineering Technologies (UBT) S.r.l. Preliminary studies5,6, support MammoWave®’ s potential use for detecting breast lesions.

CITIZEN

Citizen involvement in MammoScreen

Read more

MammoScreen’s collaborative approach empowers individuals to actively participate in shaping the future of healthcare, driving advancements, and improving patient outcomes.

Relevance and user-Centric Design

Citizens, especially those who have experienced breast cancer or have been screened for it, possess valuable insights and perspectives.

Acceptability and trust

By involving citizens, we ensure that they can contribute to the decision-making process and voice their concerns, thus enabling them to be part of the acceptance process of the technology.

Accessible and equitable Healthcare

By engaging citizens from different backgrounds, socioeconomic statuses, and geographical locations, MammoScreen hopes to identify and address potential inequities to access breast cancer screening.

Ethical considerations

Engaging citizens in the development and evaluation of MammoWave® helps addressing ethical concerns. Informed consent, privacy protection, and responsible data handling are essential aspects of any healthcare technology.

Advocacy and empowerment

By participating in the development and evaluation of this medical device, citizens can inform policies, raise awareness, and contribute to the improvement of breast cancer prevention, including screening programmes.

News and publications

Early detection is key: dont miss your cancer screening appointments

Breast, cervical and colorectal cancers are the most common in Europe but are also the most treatable when detected at an early stage. That is

Read more

Breast Cancer Awareness Month

Read more

The 5th in-person Consortium Meeting of the MammoScreen Project

Read more

MammoScreen answers questions frequently asked by clinical trial participants

Read more

Managing clinical aspects of the MammoScreen trial

Read more

1 M. Kalager, M. Zelen, F. Langmark, and H.-O. Adami, “Effect of Screening Mammography on Breast-Cancer Mortality in Norway,” New England Journal of Medicine, vol. 363, no. 13, pp. 1203–1210, Sep. 2010, doi: 10.1056/NEJMoa1000727
Broeders, M., Moss, S., Nyström, L., Njor, S., Jonsson, H., Paap, E., Massat, N., Duffy, S., Lynge, E., & Paci, E. (2012). The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies. Journal of Medical Screening, 19(1_suppl), 14–25. https://doi.org/10.1258/jms.2012.012078

2 Iwamoto, Y., Kaucher, S., Lorenz, E., Bärnighausen, T., & Winkler, V. (2019). Development of breast cancer mortality considering the implementation of mammography screening programs – a comparison of western European countries. BMC Public Health, 19(1), 823. https://doi.org/10.1186/s12889-019-7166-6

3 C. Romero Castellano et al., “Breast cancer mortality after eight years of an improved screening program using digital breast tomosynthesis,” J Med Screen, vol. 28, no. 4, pp. 456–463, Dec. 2021, doi: 10.1177/09691413211002556

4 Tagliafico AS , Houssami N . Towards consensus on managing high mammographic density in population breast screening? Breast 2023;69:422–3:S0960-9776(23)00446-0. doi:10.1016/j.breast.2023.04.004

5Rana, S.P.; Dey, M.; Loretoni, R.; Duranti, M.; Ghavami, M.; Dudley, S.; Tiberi, G. Radiation-Free Microwave Technology for Breast Lesion Detection Using Supervised Machine Learning Model. Tomography 2023, 9, 105-129. https://doi.org/10.3390/tomography9010010

6Álvarez Sánchez-Bayuela D, Ghavami N, Tiberi G, Sani L, Vispa A, Bigotti A, et al. , 2023, A multicentric, single arm, prospective, stratified clinical investigation to evaluate MammoWave’s ability in breast lesions detection. PLoS ONE 18(7): e0288312

7 https://www.webmd.com/breast-cancer/overview-risks-breast-cancer

8Cancer TODAY | IARC – https://gco.iarc.who.int
Data version: Globocan 2022 (version 1.1) – 08.02.2024
© All Rights Reserved 2025

9Miglioretti DL et al. Radiation-Induced Breast Cancer Incidence and Mortality from Digital Mammography Screening: A Modeling Study. Ann Intern Med. 2016;164(4):205–214.

10Institute of Medicine (U.S.) and National Research Council (U.S.) Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer; Joy JE, Penhoet EE, Petitti DB, editors. Saving Women’s Lives: Strategies for Improving Breast Cancer Detection and Diagnosis. Washington (DC): National Academies Press (U.S.); 2005.

11Nelson HD et al. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task
Force Recommendation. Ann Intern Med. 164(4):244-55, 2016.

1215 Oestreicher N et al. The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am J Roentgenol. 184(2);428-32:2005.